We have further characterized this regulatory signature by identifying increased E2f5, Erg1 and Csrnp1, molecules with anti-tumor properties, and Prdm1, whose gene product BLIMP-1 is a negative regulator of interferon (IFN) beta signaling. Here, PRDM1 is linked to neoplasm.